Startups
SYNTap® Biomarker Test The SYNTap Test helps physicians diagnose synucleinopathies such as: Parkinson’s, LBD, Alzheimer’s with Lewy Bodies, MCI, and MSA. Download SYNTap Spec Sheet This website is intended for the informational purposes of healthcare professionals. Parkinson’s Disease How the SYNTap Test helps improve diagnostic accuracy for various types of Parkinson’s. LEARN MORE Lewy Body […]
Overview
Location
United States, California, San Francisco
Employees
501-1000
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 9, 2026 | Amprion Receives Financing From Decathlon Capital Partners | Amprion, Inc., a San Diego, CA-based company advancing diagnosis of neurodegenerative disorders through seed-amplification testing, received a multi-million-dollar financing from Decathlon Capital Partners. The exact amount of the deal was ... |
| Oct 9, 2024 | Amprion Holds Initial $6M Close of $15M Financing | Amprion, a San Diego, CA-based developer of diagnoses of neurodegenerative disorders, announced an initial $6M closed of a $15M in Series B funding The round was led by Formation Venture Engineering (FVE) with participation by Eli Lilly and... |
| Sep 15, 2022 | Amprion Exhibits at MDS International Congress of Parkinson's Disease and Movement Disorders in Madrid and Presents Scientific Insights On SYNTap® Test at Prion2022 | Amprion, a leader in diagnostics for neurodegenerative diseases, invites researchers and practitioners attending the MDS International Congress in Madrid to visit Amprion at booth #212 and discuss how the SYNTap® Biomarker Test addresses th... |
| Sep 15, 2022 | Amprion Exhibits at MDS International Congress of Parkinson’s Disease and Movement Disorders in Madrid and Presents Scientific Insights On SYNTap® Test at Prion2022 | “The SYNTap Test fills the void for a highly sensitive and specific clinical diagnostics tool” -Amprion Chief Scientific Officer Claudio Soto, Ph.D. SAN FRANCISCO (PRWEB) September 15, 2022 Amprion, a leader in diagnostics for neurodegenera... |
| Aug 2, 2022 | Amprion Announces Research Collaboration With Mayo Clinic To Further Understand Rapidly Progressive Dementia | “This study will help us gain valuable insights to advance the molecular understanding of this highly elusive, complex, and devastating neurological condition.” Amprion CEO Russ Lebovitz, MD/Ph.D. SAN FRANCISCO (PRWEB) August 02, 2022 Ampri... |
| May 10, 2022 | Amprion Awarded NIH Grant For Analytical Validation of SYNTap® Biomarker Test For Neurological Disease | Amprion R&D Assoc Director, Luis Concha, runs experiments Amprion announces the National Institute of Neurological Disorders and Stroke (NINDS) has awarded an additional research grant of approximately $730,000 for continued validation ... |
| Apr 6, 2022 | SYNTap Biomarker Test helps doctors distinguish Parkinson’s Disease from Parkinsonism in early stages | “We are excited about the promise of molecular testing. Knowing the biomarker gives us a target for effective treatment and drug innovation. By directing proper medicine to the target biomarker, we can develop successful treatments for Park... |
| Mar 31, 2022 | Amprion Announces Commercial Rollout of SYNTap Test at the AAN Annual Meeting and Formation of Clinical Advisory Board | The SYNTap Biomarker Test helps doctors diagnose Parkinson’s, Lewy Body Dementia, and Lewy Body Variant of Alzheimer’s We invite AAN Annual Meeting attendees to visit Amprion’s booth #1074 and meet our CEO/Co-Founder and clinical director. ... |
| Jan 19, 2022 | New Insights On Alzheimer's And What It Means For Personalized Medicine | Amprion-New Insights on Alzheimer's "for the first time, the SYNTap Test enables physicians to distinguish Alzheimer's with Lewy Bodies early—during patients' lifetimes. The advent of molecular diagnostics will accelerate innovations i... |
Reviews 0
FAQ about SYNTap® Test
What has the press written about SYNTap® Test?
Parsers VC has collected 10 articles mentioning SYNTap® Test, among them “Amprion Receives Financing From Decathlon Capital Partners” (Jul 9, 2026) and “Amprion Holds Initial $6M Close of $15M Financing” (Oct 9, 2024).
Is SYNTap® Test still active?
Yes, SYNTap® Test is active; its latest activity on Parsers VC dates from Aug 13, 2026.